Abstract: A method for manufacturing a structure for microbe detection comprises the steps of: reacting nitrilotriacetic acid (NTA) and an acid anhydride to prepare a first compound; chelation of metal ions to the first compound to prepare a second compound; binding the second compound and a microbe detector to prepare a third compound; and mixing an exfoliated transition metal-dichalcogenide (TMD) compound and the third compound to prepare a structure for microbe detection, in which the metal ions of the third compound are bound with the transition metal-dichalcogenide compound.

Abstract: The present invention can provide light-colored magnetic particles having a zirconium oxide coating layer formed on a magnetic core, and having a silver coating layer formed on the zirconium oxide coating layer, and a part of the surface of the zirconium oxide coating layer is exposed to the outside, but chemical resistance is excellent, and thus the magnetic particles hardly cause a change of magnetic characteristics so as to be suitable for security elements.

Abstract: The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient, and a compound according to an aspect of the present invention, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof suppresses kinases, particularly, a TTK kinase, and thus can remarkably suppress the proliferation of cancer cells, and accordingly, can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.

Abstract: A photonic crystal film, a method for manufacturing the photonic crystal film, and an anti-forgery article comprising the photonic crystal film are disclosed. The photonic crystal film includes a polyurethane-based polymer matrix and colloidal particles dispersed in the polyurethane-based polymer matrix and arranged in a crystal lattice structure. The colloidal particles includes one or more selected from metal nanoparticles, metal oxide nanoparticles, organic nanoparticles, and carbon structure nanoparticles.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell limes, and thus can be usefully used in the treatment of lung cancer.

Abstract: A photonic crystal film, a method for manufacturing the photonic crystal film, and an anti-forgery article comprising the photonic crystal film are disclosed. The photonic crystal film includes a polyurethane-based polymer matrix and colloidal particles dispersed in the polyurethane-based polymer matrix and arranged in a crystal lattice structure. The colloidal particles includes one or more selected from metal nanoparticles, metal oxide nanoparticles, organic nanoparticles, and carbon structure nanoparticles.

Abstract: AlNiCo-based magnetic particles according to the present invention are hard magnetic particles each including: a core particle containing Al, Ni, and Co; and an inorganic shell enclosing the core particle. The core particle is an ultra-fine particle having D50 of smaller than 12 ?m, D50 being particle size corresponding to 50% in the core particle diameter cumulative distribution.

Abstract: The present invention can provide light-colored magnetic particles having a zirconium oxide coating layer formed on a magnetic core, and having a silver coating layer formed on the zirconium oxide coating layer, and a part of the surface of the zirconium oxide coating layer is exposed to the outside, but chemical resistance is excellent, and thus the magnetic particles hardly cause a change of magnetic characteristics so as to be suitable for security elements.

Abstract: The present invention relates to the manufacture of a high capacity electrode by synthesizing an excellent Li2MnO3-based composite material Li(LixNiyCozMnwO2) to improve the characteristics of an inactive Li2MnO3 material with a specific capacity of about 460 mAh/g. Here, a manufacturing method of a cathode material for a lithium secondary battery uses a Li2MnO3-based composite material Li(LixNiyCozMnwO2) by reacting a starting material wherein a nickel nitrate solution, a manganese nitrate solution and a cobalt nitrate solution are mixed, with a complex agent by co-precipitation.

Abstract: The present invention relates to a technique for manufacturing a unit cell for a solid oxide fuel cell (SOFC) which can improve the output of the unit cell of the solid oxide fuel cell, without occurring cost due to an additional process. The unit cell of the solid oxide fuel cell, comprises: a fuel electrode support body; a fuel electrode reaction layer; an electrolyte; and an air electrode, wherein the fuel electrode support body is made from an NiO and YSZ mixed material, the fuel electrode reaction layer is made from a CeScSZ and NiO mixed material, the electrolyte is made from a CeCsSZ material, and wherein the air electrode is made from an LSM and CeScSZ mixed material.

Abstract: The present invention relates to a technique for manufacturing a unit cell for a solid oxide fuel cell (SOFC) which can improve the output of the unit cell of the solid oxide fuel cell, without occurring cost due to an additional process. The unit cell of the solid oxide fuel cell, comprises: a fuel electrode support body; a fuel electrode reaction layer; an electrolyte; and an air electrode, wherein the fuel electrode support body is made from an NiO and YSZ mixed material, the fuel electrode reaction layer is made from a CeScSZ and NiO mixed material, the electrolyte is made from a CeCsSZ material, and wherein the air electrode is made from an LSM and CeScSZ mixed material.

Abstract: Provided is a method for synthesizing air electrode powder, which uses instead of an organic solvent lanthanum-nitrate, strontium-nitrate, cobalt-nitrate, and iron-nitrate, which are affordable and can undergo water-based synthesis, by controlling additional mol ratio and a synthesis temperature of a chelate agent and an esterification reaction accelerating agent instead of complex process controlling conditions, such as a hydrolysis condition and pH in order to control particle shape.

Abstract: The present invention relates to the manufacture of a high capacity electrode by synthesizing an excellent Li2MnO3-based composite material Li(LixNiyCozMnwO2) to improve the characteristics of an inactive Li2MnO3 material with a specific capacity of about 460 mAh/g. Here, a manufacturing method of a cathode material for a lithium secondary battery uses a Li2MnO3-based composite material Li(LixNiyCozMnwO2) by reacting a starting material wherein a nickel nitrate solution, a manganese nitrate solution and a cobalt nitrate solution are mixed, with a complex agent by co-precipitation.

Abstract: The present invention relates to a method for manufacturing unit cells of a solid oxide fuel cell through a process of attaching a fuel electrode reaction layer/electrolyte layer film assembly, manufactured using a tape casting method, onto a fuel electrode support (sintered body) which consists of the unit cells of the solid oxide fuel cell and which is manufactured using a tape casting method, a pressure method, a discharge plasma method, or the like.

Abstract: A manufacturing method for a solid oxide fuel cell (SOFC) unit cell is disclosed. The manufacturing method may include manufacturing an Ni—CeScSZ anode layer; manufacturing a CeScSZ electrolyte layer; manufacturing a gadolinia-doped ceria (GDC) buffer layer; and manufacturing a lanthanum strontium cobalt ferrite (LSCF) cathode layer. Accordingly, an ohmic resistance of electrolyte and a polarization resistance may be reduced and high output may be obtained even at a middle low temperature.

Abstract: Disclosed is a novel use of apigenin as a chondroregenerative agent, which has the effects of reducing elevated of cartilage destruction markers including total synovial fluid volume and proteoglycan, total proteins and prostaglandin in a synovial fluid, improving the condition of synovial cells, and regenerating cartilage. Also, the present invention discloses a therapeutic agent for osteoarthritis comprising apigenin as an agent regenerating articular cartilage, and a method of treating osteoarthritis using such a therapeutic agent.